Assessment of the environmental fate and effects of azilsartan, a selective antagonist of angiotensin II type 1.

In this paper the results of a thorough evaluation of the environmental fate and effects of azilsartan are presented. Azilsartan medoxomil is administered as a pro-drug for the treatment of patients with essential hypertension. The pro-drug is converted by hydrolysis to the active pharmaceutical ingredient azilsartan. Laboratory tests to evaluate the environmental fate and effects of azilsartan medoxomil were conducted with azilsartan and performed in accordance with OECD test guidelines. The predicted environmental concentration (PEC) in surface water was estimated at 0.32 µg L(-1) (above the action limit of 0.01 µg L(-1)), triggering a Phase II assessment. Azilsartan is not readily biodegradable. Results of the water sediment study demonstrated significant shifting of azilsartan metabolites to sediment. Based on the equilibrium partitioning method, metabolites are unlikely to pose a risk to sediment-dwelling organisms. Ratios of the predicted environmental concentrations (PECs) to the predicted-no-effect concentrations (PNECs) did not exceed the relevant triggers, and the risk to aquatic, sewage treatment plant (STP), groundwater and sediment compartments was concluded acceptable. A terrestrial assessment was not triggered. Azilsartan poses an acceptable risk to the environment.

Development of a bioassay to test the possible role of thiamine disturbance as a mechanism behind pollution-induced reproductive failures in birds.

A test system was developed to examine the effects of environmental contaminants on thiamine homeostasis in bird embryos. This system employs fresh chicken egg yolk lipids as a vehicle for use in egg injection studies. Furazolidone, an antibiotic suspected to interfere with thiamine metabolism, was used as a positive control to evaluate the utility of the test system. It was determined that fresh chicken egg yolk lipids were preferable over chemical vehicles as it resulted in lower mortality rates (16% versus 23-62%) and did not induce any observable effects in the embryo. Injection of 1 mg/egg of furazolidone at day 0 of development resulted in decreased respiration followed by death, with mortality rates being twice as high as in carrier controls. In addition, transketolase activity, which was measured as an indicator of thiamine availability in the body, was decreased 25% in brains of 19-day-old embryos. This mechanism may be of importance for effects of environmental contaminants in wild bird populations.